Paris - Delayed Quote EUR

Oncodesign Precision Medicine Société anonyme (ALOPM.PA)

0.3800

+0.0090

+(2.43%)

At close: April 25 at 5:35:25 PM GMT+2

OPM Announces Its 2024 Annual Results and Clinical Developments

DIJON, France, April 03, 2025--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces its 2024 financial results, approved by the Board of Directors on April 3, 2025.

Business Wire 24 days ago

ALOPM.PA
+2.43%
Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1

DIJON, France, March 24, 2025--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Ticker: ALOPM), a clinical-stage company developing innovative therapies to overcome immune evasion and drug resistance, today announced the submission to Swiss authorities of the study protocol for its Phase 1b/2a clinical trial REVERT (RIPK2 for rEsistant and adVanced mElanoma tReatmenT) with OPM-101, its RIPK2 inhibitor in advanced melanoma patients with resistance to anti-PD-1. This submi

Business Wire last month

ALOPM.PA
+2.43%
Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors

DIJON, France, March 04, 2025--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the appointment of Christophe Thurieau, Executive Director Research at Servier, as a member of the Board of Directors.

Business Wire last month

ALOPM.PA
+2.43%
Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers

DIJON, France, December 20, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announces the reacquisition of the rights to its OPM-201 program in the treatment of Parkinson’s disease from Servier laboratories.

Business Wire 4 months ago

ALOPM.PA
+2.43%
OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

DIJON, France, October 22, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today confirms and details the final results of its Phase 1 clinical trial with OPM-101, its RIPK2 inhibitor and drug candidate administered orally to healthy volunteers, first reported on July 16, 2024. This clinical trial began in February 2023, the datab

Business Wire 6 months ago

ALOPM.PA
+2.43%
OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

DIJON, France, October 15, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced that a scientific abstract on its leading drug candidate, OPM-101, has been presented at the United European Gastroenterology (UEG) Week congress, October 12-15, 2024, in Vienna, Austria.

Business Wire 6 months ago

ALOPM.PA
+2.43%
OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

DIJON, France, September 25, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced its financial results for the first half of 2024, approved by the Board of Directors on September 25, 2024.

Business Wire 6 months ago

ALOPM.PA
+2.43%
OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

DIJON, France, July 16, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, today announced positive results of phase 1 trial testing the drug candidate OPM-101, administered orally in single ascending doses (SAD) and multiple ascending doses (MAD), in healthy volunteers (HV).

Business Wire 9 months ago

ALOPM.PA
+2.43%
Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

DIJON, France, May 15, 2024--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of Precision Medicine applications based on the Affilin® technology platform, announce the signature of a strategic collaboration agreement for

Business Wire 11 months ago

ALOPM.PA
+2.43%

Performance Overview

Return	ALOPM.PA	CAC 40 (^FCHI)
YTD	-46.78%	+2.11%
1-Year	-74.75%	-5.99%
3-Year	-55.29%	+16.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Oncodesign Precision Medicine Société anonyme (ALOPM.PA)

OPM Announces Its 2024 Annual Results and Clinical Developments

Oncodesign Precision Medicine (OPM) Announces Protocol Submission for its Phase 1b/2a Study, REVERT for OPM-101 in Combination with Pembrolizumab in Patients with Advanced Melanoma Resistant to Anti-PD1

Nomination of Christophe Thurieau as an Independent Member of OPM Board of Directors

Oncodesign Precision Medicine Reacquires Rights to Its OPM-201 Program From Servier After a Positive Phase I Trial in Healthy Volunteers

OPM Reports Final Results of Its Phase 1 Study With RIPK2 Inhibitor OPM-101, With Strong Safety Data and No Cardiac Toxicity, Paving the Way for the Launch of Phase 1b/2a

OPM Announces Poster Presentation on OPM-101, a RIPK2 Kinase Inhibitor, in Healthy Volunteers at UEG Week 2024 Conference

OPM Announces Its First-half 2024 Results and Provides an Update on Its Clinical Developments, and Its Financial Situation

OPM Announces Positive Results of Its Phase 1 in Healthy Volunteers with OPM-101: Strong Target Engagement With Excellent Safety Profile

Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents

Performance Overview